Wechselwirkungen · Inhixa
Inhixa 50,000 IU (500 mg)/5 mL solution for injection in multidose container · Abschnitt 4.5 · PDF-Seite 243
HOS-137199 · Präparat HOS-097950
It is recommended that some agents which affect haemostasis should be discontinued prior to enoxaparin sodium therapy unless strictly indicated. If the combination is indicated, enoxaparin sodium should be used with careful clinical and laboratory monitoring when appropriate. These agents include medicinal products such as: - Systemic salicylates, acetylsalicylic acid at anti-inflammatory doses, and NSAIDs including ketorolac, - Other thrombolytics (e.g. alteplase, reteplase, streptokinase, tenecteplase, urokinase) and anticoagulants (see section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sodium (HOS-109681) reteplase (HOS-136922) streptokinase (HOS-135121) alteplase (HOS-136921) tenecteplase (HOS-091171) urokinase (HOS-136923) ketorolac (HOS-136919)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-16T09:35:00Z · SHA-256 bbb8302fcca3a170cc14307df6fa307c1fd979d2c3ae4a14f42ba825950d23d7 · Passage 7b67e4827e9071eddd8e44fed55281eac595b87211ab62873db333e980abc3dd · Zeichen 93–699 im Abschnitt